Stroshane R M, Koss R F, Biddlecome C E, Luczkowec C, Edelson J
J Pharm Sci. 1984 Oct;73(10):1438-41. doi: 10.1002/jps.2600731029.
Thirty-nine healthy men received milrinone either orally or intravenously in two separate double-blind, placebo-controlled studies. The mean bioavailability, based on the area under the plasma concentration versus time curves, was 0.92. The plasma data for those subjects in the intravenous study were described by an open two-compartment model with a mean (+/- SD) apparent first-order terminal elimination rate constant (beta) of 0.86 (+/- 0.23) h-1, which corresponds to a half-life of 0.8 h. In the intravenous study, the renal clearance and total body clearance were 21.1 and 25.9 L/h, respectively. The corresponding values in the oral study were 23.8 and 29.7 L/h. Between 79.9 and 84.5% of the total doses were recovered in the urine samples taken at 0-24 h.
在两项独立的双盲、安慰剂对照研究中，39名健康男性接受了米力农口服或静脉注射。基于血浆浓度-时间曲线下面积，平均生物利用度为0.92。静脉注射研究中受试者的血浆数据用开放二室模型描述，平均（±标准差）表观一级末端消除速率常数（β）为0.86（±0.23）h⁻¹，对应半衰期为0.8小时。在静脉注射研究中，肾脏清除率和全身清除率分别为21.1和25.9L/h。口服研究中的相应值分别为23.8和29.7L/h。在0至24小时采集的尿液样本中，回收了总剂量的79.9%至84.5%。
